Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponsegromab in cancer cachexia
NCT04299048Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2020
- Primary completion
- Mar 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ponsegromab in cachexia, sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events at 24 weeks, Number of Participants With Laboratory Test Abnormalities at 24 weeks and 2 more. Started Nov 2020; status: completed.
02
Drugs
ponsegromab
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT04299048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04299048.